CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.

Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 14 11 2023
accepted: 05 03 2024
revised: 28 02 2024
medline: 16 3 2024
pubmed: 16 3 2024
entrez: 16 3 2024
Statut: aheadofprint

Résumé

Chimeric antigen receptor (CAR) T cells targeting CD22 (CD22-CAR) provide a therapeutic option for patients with CD22

Identifiants

DOI: 10.1038/s41375-024-02220-y PMID: 38491306
pubmed: 38491306
doi: 10.1038/s41375-024-02220-y
pii: 10.1038/s41375-024-02220-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Boyd SD, Natkunam Y, Allen JR, Warnke RA. Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol. 2013;21:116–31.
doi: 10.1097/PAI.0b013e31825d550a pubmed: 22820658 pmcid: 4993814
Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34:1202–7.
doi: 10.1038/s41375-019-0580-z pubmed: 31591467
Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165–74.
doi: 10.1182/blood-2012-06-438002 pubmed: 23243285 pmcid: 3575759
Shah NN, Stevenson MS, Yuan CM, Richards K, Delbrook C, Kreitman RJ, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:964–9.
doi: 10.1002/pbc.25410 pubmed: 25728039 pmcid: 4405453
Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10:702–23.
doi: 10.1158/2159-8290.CD-19-0945 pubmed: 32193224 pmcid: 7939454
Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a Phase I Anti-CD22 CAR T-cell trial. J Clin Oncol. 2020;38:1938–50.
doi: 10.1200/JCO.19.03279 pubmed: 32286905 pmcid: 7280047
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T-cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.
doi: 10.1056/NEJMoa1407222 pubmed: 25317870 pmcid: 4267531
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.
doi: 10.1056/NEJMoa1709866 pubmed: 29385370 pmcid: 5996391
Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston ICD, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy. Cytotherapy. 2016;18:1002–11.
doi: 10.1016/j.jcyt.2016.05.009 pubmed: 27378344
Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018;20:394–406.
doi: 10.1016/j.jcyt.2017.09.005 pubmed: 29287970
Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a Phase 1 dose escalation and expansion trial. Nat Med. 2020;26:1569–75.
doi: 10.1038/s41591-020-1081-3 pubmed: 33020647
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20–28.
doi: 10.1038/nm.4441 pubmed: 29155426
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625–38.
doi: 10.1016/j.bbmt.2018.12.758 pubmed: 30592986
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transpl Cell Ther. 2023;29:438.e1–438.e16.
doi: 10.1016/j.jtct.2023.03.006
Baird JH, Frank MJ, Craig J, Patel S, Spiegel JY, Sahaf B, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2021;137:2321–5.
doi: 10.1182/blood.2020009432 pubmed: 33512414 pmcid: 8085484
O’Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA Approval Summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25:1142–6.
doi: 10.1158/1078-0432.CCR-18-2035 pubmed: 30309857
Bouchkouj N, Lin X, Wang X, Przepiorka D, Xu Z, Purohit-Sheth T, et al. FDA Approval Summary: brexucabtagene autoleucel for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Oncologist. 2022;27:892–9.
doi: 10.1093/oncolo/oyac163 pubmed: 35983953 pmcid: 9526496
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502.
doi: 10.1016/S0140-6736(21)01222-8 pubmed: 34097852
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR s with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419–31.
doi: 10.1038/s41591-021-01436-0 pubmed: 34312556 pmcid: 8363505
Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, et al. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. Blood. 2022;140:451–63.
doi: 10.1182/blood.2022015795 pubmed: 35605184 pmcid: 9353146
Wang T, Tang Y, Cai J, Wan X, Hu S, Lu X, et al. Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial. J Clin Oncol. 2023;41:1670–83.
doi: 10.1200/JCO.22.01214 pubmed: 36346962
Pan J, Tang K, Luo Y, Seery S, Tan Y, Deng B, et al. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2023;24:1229–41.
doi: 10.1016/S1470-2045(23)00436-9 pubmed: 37863088
Arnaudo L. On CAR-Ts, decentralized in-house models, and the hospital exception. Routes for sustainable access to innovative therapies. J Law Biosci. 2022;9:lsac027.
doi: 10.1093/jlb/lsac027 pubmed: 36168389 pmcid: 9507023
Fried S, Shouval R, Varda-Bloom N, Besser MJ, Yerushalmi R, Shem-Tov N, et al. Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel. Leuk Lymphoma. 2022;63:3385–93.
doi: 10.1080/10428194.2022.2123232 pubmed: 36111694
de Macedo Abdo L, Barros LRC, Saldanha Viegas M, Vieira Codeço Marques L, de Sousa Ferreira P, Chicaybam L, et al. Development of CAR- therapy for B-ALL using a point-of-care approach. Oncoimmunology. 2020;9:1752592.
doi: 10.1080/2162402X.2020.1752592 pubmed: 32363126 pmcid: 7185214
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2:408–22.
doi: 10.1158/2643-3230.BCD-21-0084 pubmed: 34568831 pmcid: 8462122

Auteurs

Liora M Schultz (LM)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.

Nikeshan Jeyakumar (N)

Division of Hematology, Stanford University, Stanford, CA, USA.

Anne Marijn Kramer (AM)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
ORCID: 0000-0001-5239-7343

Bita Sahaf (B)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.

Hrishi Srinagesh (H)

Division of Hematology, Stanford University, Stanford, CA, USA.

Parveen Shiraz (P)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Neha Agarwal (N)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Mark Hamilton (M)

Division of Hematology, Stanford University, Stanford, CA, USA.

Courtney Erickson (C)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.

Ashley Jacobs (A)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.

Jennifer Moon (J)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.

Christina Baggott (C)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.

Sally Arai (S)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Sushma Bharadwaj (S)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Laura J Johnston (LJ)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Michaela Liedtke (M)

Division of Hematology, Stanford University, Stanford, CA, USA.

Robert Lowsky (R)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Everett Meyer (E)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Robert Negrin (R)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Andrew Rezvani (A)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Judy Shizuru (J)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
ORCID: 0000-0003-3246-4726

Surbhi Sidana (S)

Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
ORCID: 0000-0003-3288-7614

Emily Egeler (E)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.

Sharon Mavroukakis (S)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.

Ramya Tunuguntla (R)

Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

Nikolaos Gkitsas-Long (N)

Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

Aidan Retherford (A)

Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

Annie Kathleen Brown (AK)

Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

Anne-Louise Gramstrap-Petersen (AL)

Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

Raquel Martin Ibañez (RM)

Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

Steven A Feldman (SA)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Laboratory for Cell and Gene Medicine, Stanford University, Stanford, CA, USA.

David B Miklos (DB)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.
ORCID: 0000-0003-0717-4305

Crystal L Mackall (CL)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
ORCID: 0000-0001-6323-4304

Kara L Davis (KL)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.

Matthew Frank (M)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.
Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA.

Sneha Ramakrishna (S)

Division of Pediatric Hematology/Oncology, Stanford University, Stanford, CA, USA.
Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA.

Lori Muffly (L)

Center for Cancer Cell Therapy, Stanford University, Stanford, CA, USA. lmuffly@stanford.edu.
Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA, USA. lmuffly@stanford.edu.
ORCID: 0000-0002-9887-6136

Classifications MeSH